Patients undergoing general anesthesia
Conditions
Interventions
Using a simulation model, set the continuous intravenous infusion rate so that the effect site concentration from continuous intravenous remimazolam infusion is (1) 0.2 micro g/ml and (2) 0.5 micro g/
Sponsors
Shinshu University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (i) Patients 20 years of age or older at the time of obtaining consent (ii) Patients undergoing general anesthesia with remimazolam (iii) Patients who have given a full explanation of their participation in this study and who have given written consent based on their own free will.
Exclusion criteria
Exclusion criteria: (1) Patients with ASA-PS of 3 or higher (2) Patients undergoing surgery for malignant tumors, and patients for whom the site of electrode application is the surgical site (3) Patients diagnosed with diabetes, dementia, or epilepsy (4) Patients with a pacemaker, implantable cardioverter-defibrillator, or deep brain stimulator (5) Patients with skin lesions or numbness at the electrode site (6) Patients with communication difficulties (e.g., non-Japanese speakers, patients with mental retardation, patients with consciousness disorders) (7) Pregnant patients (8) Patients with allergy to remimazolam or other benzodiazepines (9) Other patients who are judged by the investigator to be difficult to conduct the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Amplitude of nociceptive evoked potentials | — |
Secondary
| Measure | Time frame |
|---|---|
| Latency of nociceptive evoked potentials, NRS, BIS index, MOAA/S | — |
Countries
Japan
Contacts
Public ContactKunihiro Mitsuzawa
Shinshu University School of Medicine The Department of Anesthesiology and Resuscitology
Outcome results
None listed